Core Viewpoint - The legal opinion letter addresses the adjustment of performance assessment indicators for the 2025 restricted stock incentive plan of Guangzhou Ruisheng Intelligent Technology Co., Ltd. [1][2][4] Group 1: Approval and Authorization of Adjustments - The adjustments to the performance assessment indicators have been approved and authorized by the company's board of directors, in accordance with relevant laws and regulations [7][8][10] - The adjustments are necessary to ensure the smooth implementation of the incentive plan and to motivate the company's team effectively [12][13] Group 2: Specific Adjustments to Performance Indicators - The performance assessment for the incentive plan will now include both net profit growth rate and non-recurring net profit growth rate, with 2024 as the base year [16][17] - The adjusted performance targets for the first vesting period in 2025 are set at a target value of 170% and a trigger value of 140% for net profit growth rate [15][17] - For the second vesting period in 2026, the target value is set at 260% and the trigger value at 230% for net profit growth rate [15][17] Group 3: Compliance and Conclusion - The adjustments comply with the relevant regulations and do not harm the interests of the company and its shareholders [19][20] - The adjustments still require approval from the company's shareholders' meeting to be fully enacted [19][20]

证券代码：688676 证券简称：金盘科技 公告编号：2025-059 海南金盘智能科技股份有限公司 关于作废部分已授予尚未归属的 2021 年限制性股票的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 海南金盘智能科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开第 三届董事会第二十六次会议，审议通过了《关于作废部分已授予尚未归属的 2021 年限 制性股票的议案》。根据公司 2021 年限制性股票激励计划规定，各归属期对激励对象 需进行绩效考核，所授予但尚未归属的限制性股票将予以作废处理。现将有关事项说明 如下： 一、本次激励计划已履行的决策程序和信息披露情况 （一）2021 年 9 月 23 日，公司召开第二届董事会第十四次会议，审议通过了《关 于 <公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草案="草案"> 及其摘要的议 案》、《关于 <公司 ensp="ensp"> 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办 理 ...

Core Points - The company has implemented a restricted stock incentive plan, distributing a total of 500,000 shares, which represents 1.089% of the company's total equity at the time of the announcement [1][2] - The plan includes two categories of incentive recipients: A Class (executives and core technical personnel) and B Class (mid-level management and key business personnel) [1] - A total of 400,000 shares, or 80% of the plan, are initially granted, with an additional 100,000 shares reserved for future allocation [1] Distribution Details - A Class recipients include executives and core technical personnel, while B Class consists of 17 mid-level managers and key personnel [1] - The shares allocated to B Class recipients amount to 12,200 shares, which is 2.44% of the total shares granted [1] - The reserved portion of the plan accounts for 20% of the total shares, equating to 100,000 shares [1]

Core Viewpoint - The company has developed a restrictive stock incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and employees for long-term development [1][2] Group 1: Purpose and Principles of the Assessment - The purpose of the assessment is to establish a long-term incentive mechanism to attract and retain talent while aligning the interests of shareholders, the company, and employees [2] - The assessment is based on principles that ensure shareholder interests are protected, following relevant laws and regulations [2] Group 2: Assessment Organization - The Compensation and Assessment Committee is responsible for leading and organizing the assessment of incentive participants [2] - A dedicated assessment team will be formed to implement the assessment, reporting to the Compensation and Assessment Committee [2] Group 3: Assessment Scope - The assessment applies to all participants in the stock incentive plan, including senior management, core technical personnel, and key business staff [2][3] Group 4: Assessment Indicators and Standards - The performance assessment for the company will be based on revenue and net profit targets for the years 2025 to 2027 [3][4] - Specific targets include: - 2025: Revenue of 86.25 billion and net profit of 7.19 billion - 2026: Revenue of 103.50 billion and net profit of 8.63 billion - 2027: Revenue of 124.20 billion and net profit of 10.35 billion [4] Group 5: Personal Performance Assessment - Individual performance will be assessed based on internal criteria, with results categorized into six levels, affecting the personal share of stock [4] Group 6: Assessment Procedures and Results Management - The assessment team will maintain records and submit performance reports to the Compensation and Assessment Committee [4][5] - Assessment results will be communicated to participants within five working days, with an option for appeal [4][5] Group 7: Additional Provisions - The board of directors is responsible for the formulation, interpretation, and revision of the assessment methods [6] - The plan will be implemented after approval by the shareholders' meeting [6]

Core Viewpoint - Shenzhen Oat Technology Co., Ltd. has announced adjustments to the grant prices of its restricted stock incentive plans for 2022 and 2023, reducing the grant price from 9.02 CNY to 8.53 CNY for 2022 and from 5.61 CNY to 5.12 CNY for 2023 [1][10]. Group 1: Adjustment Details - The grant price for the 2022 restricted stock incentive plan has been adjusted from 9.02 CNY per share to 8.53 CNY per share [1][10]. - The grant price for the 2023 restricted stock incentive plan has been adjusted from 5.61 CNY per share to 5.12 CNY per share [1][10]. - The adjustments were made in accordance with the company's incentive plan regulations, considering factors such as capital increases and dividend distributions [9][10]. Group 2: Decision-Making Process - The board of directors and the supervisory board have reviewed and approved the adjustments, ensuring compliance with relevant laws and regulations [1][10]. - Independent directors provided opinions affirming that the adjustments are beneficial for the company's sustainable development and do not harm the interests of shareholders [1][10]. - The supervisory board has verified the eligibility of the incentive recipients and the conditions for granting the stock [8][10]. Group 3: Impact and Legal Opinions - The adjustments to the grant prices are not expected to have a substantial impact on the company's financial status and operational results [10]. - Legal opinions confirm that the adjustments and related matters have received the necessary approvals and comply with applicable laws and regulations [11].

Core Points - The company has reviewed and approved the list of 27 incentive recipients for the 2023 restricted stock incentive plan, confirming their eligibility under relevant laws and regulations [1][2] - A total of 235,762 shares of restricted stock will be granted to the approved recipients, which aligns with legal and regulatory requirements and does not harm the interests of the company and its shareholders [2] Summary by Sections - **Eligibility and Compliance** - The 27 incentive recipients meet the qualifications set forth by the Company Law, Securities Law, and other relevant regulations, confirming their legal and effective status as recipients of the incentive plan [1] - **Stock Allocation** - The total number of restricted shares to be granted is 235,762, which complies with all applicable laws and regulations [2]

| 深圳市他山企业管理咨询有限公司 | | | --- | --- | | 关于深圳市燕麦科技股份有限公司 | | | 预留授予部分第一个归属期符合归属条件事项的 | | | 独立财务顾问报告 | | | 二〇二五年八月 | | | 目 录 | | | 深圳市他山企业管理咨询有限公司 | 独立财务顾问报告 | | 释 义 | | | 除非上下文文意另有所指，下列词语具有如下含义： | | | 燕麦科技、公司 指 | 深圳市燕麦科技股份有限公司 | | 深圳市燕麦科技股份有限公司 | 2023 年限制性股票激励 | | 本激励计划 指 | | | 计划 | | | 《深圳市燕麦科技股份有限公司 | 2023 年限制性股票激 | | 《股权激励计划（草案）》 指 | | | 励计划（草案）》 | | | 《深圳市他山企业管理咨询有限公司关于深圳市燕麦 | | | 科技股份有限公司 2023 | 年限制性股票激励计划调整事 | | 独立财务顾问报告、本报告 指 | | | 项及预留授予部分第一个归属期符合归属条件事项的 | | | 独立财务顾问报告》 | | | 限制性股票、第二类限制性 | 满足归属条件后，按本激 ...

Core Viewpoint - Shenzhen Oat Technology Co., Ltd. has announced the first vesting period of its 2023 restricted stock incentive plan, confirming that the conditions for vesting have been met for a total of 23.5762 million shares [1][12][18] Summary by Sections Incentive Plan Overview - The total number of restricted stocks granted is 3.021524 million shares, with 2.55 million shares for the first grant (84.39%) and 471524 shares reserved (15.12%) [1] - The purchase price for the restricted stocks is set at 5.12 yuan per share [1][11] Vesting Arrangement - The first vesting period for the initial grant is from the first trading day after 16 months to the last trading day within 28 months [2] - The second vesting period for the initial grant is from the first trading day after 28 months to the last trading day within 40 months [2] - The first vesting period for the reserved grant is from the first trading day after 12 months to the last trading day within 24 months [2] - The second vesting period for the reserved grant is from the first trading day after 24 months to the last trading day within 36 months [2] Performance Assessment - The performance assessment for the first vesting period requires a revenue growth rate of no less than 10% for 2024 based on 2023 revenue [3][5] - Alternatively, a net profit growth rate of no less than 15% for 2024 based on 2023 net profit is also acceptable [3] - The performance assessment for the second vesting period requires a revenue growth rate of no less than 20% for 2025 based on 2023 revenue [5] - Alternatively, a net profit growth rate of no less than 30% for 2025 based on 2023 net profit is also acceptable [5] Compliance and Approval - The board of directors and the supervisory board have approved the incentive plan and confirmed that the vesting conditions have been met for the reserved grant [12][18] - A total of 27 individuals are eligible for the reserved grant, with the vesting conditions confirmed [12][18] Financial Reporting and Accounting - The company will account for the stock-based compensation in accordance with relevant accounting standards, using the Black-Scholes model to determine the fair value of the restricted stocks [17] - The company will adjust the expected number of vested shares based on changes in eligible individuals and the completion of vesting conditions [17]

证券代码：688426 证券简称：康为世纪 公告编号：2025-030 事会第十四次会议审议，通过了《关于 2024 年限制性股票激励计划第一个归属 期不符合归属条件暨作废已授予尚未归属的限制性股票的议案》，同意对 2024 年限制性股票激励计划中已获授但尚未归属的第二类限制性股票 2,098,400 股全 部取消归属，并作废失效。 江苏康为世纪生物科技股份有限公司 关于 2024 年限制性股票激励计划第一个归属期不符合 归属条件暨作废已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开的第二届董事会第十六次会议和第二届监事会第十四次会议审议通过了 《关于 2024 年限制性股票激励计划第一个归属期不符合归属条件暨作废已授予 尚未归属的限制性股票的议案》，同意对 2024 年限制性股票激励计划中已获授但 尚未归属的第二类限制性股票 2,098,400 股全部取消归属，并作废失效。其中 失去了激励资格须予以作 ...

Meeting Overview - The second board meeting of Beijing Innotech Biotechnology Co., Ltd. was held on August 27, 2025, with all 9 directors present, and the meeting complied with relevant laws and regulations [1]. Financial Reports - The board approved the 2025 semi-annual report and its summary with a unanimous vote of 9 in favor [2]. - The board also approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and proper use of funds [2]. Cash Management - The board agreed to use up to RMB 300 million of idle raised funds for cash management, allowing for the purchase of safe and liquid financial products, with a rolling usage period from September 2, 2025, to September 1, 2026 [3]. - Additionally, the board approved the use of up to RMB 1.7 billion of idle self-owned funds for similar cash management purposes during the same period [4]. Stock Incentive Plan - The board approved an adjustment to the grant price of the 2023 restricted stock incentive plan from RMB 13.20 per share to RMB 12.65 per share [5]. - A semi-annual evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was also approved [6]. Corporate Governance Changes - The board approved changes to the registered capital and the cancellation of the supervisory board, allowing the audit committee to assume its responsibilities [7]. - The board agreed to revise and add certain company regulations to enhance governance structure [8]. Fund Allocation - The board approved the use of RMB 60 million of surplus raised funds for the "In Vitro Diagnostic Product R&D Project" and extended the project's timeline by 18 months [10]. Stock Incentive Plan Draft - The board approved the draft of the 2025 restricted stock incentive plan, which aims to attract and retain talent while aligning interests among shareholders, the company, and core team members [11][13]. Authorization for Stock Incentive Plan - The board proposed to seek shareholder authorization for handling matters related to the 2025 restricted stock incentive plan [15]. Insurance for Directors - A proposal for purchasing liability insurance for directors and supervisors was submitted for shareholder approval due to the absence of a valid resolution [17]. Shareholder Meeting - The board approved a proposal to convene the first extraordinary general meeting of shareholders in 2025 [14].